000142855 001__ 142855
000142855 005__ 20240229112531.0
000142855 0247_ $$2doi$$a10.1016/j.cgh.2017.12.038
000142855 0247_ $$2pmid$$apmid:29306042
000142855 0247_ $$2ISSN$$a1542-3565
000142855 0247_ $$2ISSN$$a1542-7714
000142855 037__ $$aDKFZ-2019-00485
000142855 041__ $$aeng
000142855 082__ $$a610
000142855 1001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b0$$eFirst author$$udkfz
000142855 245__ $$aAssociations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review.
000142855 260__ $$aNew York, NY$$bElsevier Science$$c2019
000142855 3367_ $$2DRIVER$$aarticle
000142855 3367_ $$2DataCite$$aOutput Types/Journal article
000142855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551092009_18216$$xReview Article
000142855 3367_ $$2BibTeX$$aARTICLE
000142855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142855 3367_ $$00$$2EndNote$$aJournal Article
000142855 520__ $$aColorectal cancer (CRC) is a heterogeneous disease with different mechanisms of pathogenesis. Classification systems have been proposed based on molecular features of tumors, but none are used in clinical practice. We performed a systematic review of studies on the associations between molecular classifications of CRC and patient survival.We searched the PubMed, Embase, Cochrane, and Web of Science databases for combinations of terms related to CRC, molecular markers, subtype classifications, and survival (overall survival, disease-specific survival, disease-free survival). We included only studies that used at least 3 molecular markers to classify tumors and provided an estimate of survival associated with each subtype. Data extraction and quality assessment were performed independently by 2 reviewers.We identified 6 studies that fulfilled the inclusion criteria. In these studies, molecular subtypes were assigned based on pathways associated with tumor development or findings from gene expression clustering analyses. Most studies proposed classification systems with 5 subtypes, including information on microsatellite instability, mutations in BRAF, and mutations in KRAS. None of the studies included TNM stage in their classification system. Three classification systems used similar definitions. Only 3 studies provided internal or external validation of the proposed classification schemes. Tumors with microsatellite stability and mutations in KRAS or BRAF were associated with decreased survival times, compared with tumors with microsatellite stability and no mutations.In a systematic review of studies of molecular classifications of CRC and patient survival, we found that most subtypes were not significantly or not differentially associated with survival. None of the systems integrated TNM staging. Further research and validation are needed to develop molecular subtype classification systems for clinical practice.
000142855 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142855 588__ $$aDataset connected to CrossRef, PubMed,
000142855 7001_ $$0P:(DE-He78)72d22b0cfac00f2fc21ceb7236804af0$$aJia, Min$$b1$$udkfz
000142855 7001_ $$aKloor, Matthias$$b2
000142855 7001_ $$aBläker, Hendrik$$b3
000142855 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000142855 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5$$eLast author$$udkfz
000142855 773__ $$0PERI:(DE-600)2102638-5$$a10.1016/j.cgh.2017.12.038$$gVol. 17, no. 3, p. 402 - 410.e2$$n3$$p402 - 410.e2$$tClinical gastroenterology and hepatology$$v17$$x1542-3565$$y2019
000142855 909CO $$ooai:inrepo02.dkfz.de:142855$$pVDB
000142855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)72d22b0cfac00f2fc21ceb7236804af0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142855 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142855 9141_ $$y2019
000142855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN GASTROENTEROL H : 2017
000142855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142855 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142855 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142855 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142855 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN GASTROENTEROL H : 2017
000142855 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142855 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000142855 980__ $$ajournal
000142855 980__ $$aVDB
000142855 980__ $$aI:(DE-He78)C070-20160331
000142855 980__ $$aI:(DE-He78)C120-20160331
000142855 980__ $$aUNRESTRICTED